AR075367A1 - Inhibidores de glucosilceramida sintasa - Google Patents
Inhibidores de glucosilceramida sintasaInfo
- Publication number
- AR075367A1 AR075367A1 ARP100100326A ARP100100326A AR075367A1 AR 075367 A1 AR075367 A1 AR 075367A1 AR P100100326 A ARP100100326 A AR P100100326A AR P100100326 A ARP100100326 A AR P100100326A AR 075367 A1 AR075367 A1 AR 075367A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- independently
- ora1
- bond
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- 101000743846 Diplobatis ommata Ras-related protein Rab-10 Proteins 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 101001013022 Homo sapiens Migration and invasion enhancer 1 Proteins 0.000 abstract 2
- 102100029624 Migration and invasion enhancer 1 Human genes 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical group C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 abstract 1
- 102220465932 Beta-1,3-glucuronyltransferase LARGE2_R13A_mutation Human genes 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 101000829425 Homo sapiens Steroid receptor RNA activator 1 Proteins 0.000 abstract 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 abstract 1
- 102100023706 Steroid receptor RNA activator 1 Human genes 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 101150007570 nra-1 gene Proteins 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Además comprende una composicion que contiene los compuestos, N-oxidos, y/o sus sales aceptables para uso farmacéutico, y el uso de los compuestos y las composiciones para tratar enfermedades en las cuales la GCS es un mediador o está implicada. Además comprende el uso de los compuestos en y para la preparacion de medicamentos, en particular para tratar enfermedades en las cuales la GCS es un mediador o está implicada. Reivindicacion 1: Un compuesto de la formula (1), o un estereoisomero simple o mezcla de estereoisomeros de los mismos sus N-oxidos, y además opcionalmente como su sal aceptable para uso farmacéutico, donde A es isopropilo, t-butilo, cicloalquilo C3-8, heterociclilo, arilo, o heteroarilo, donde el cicloalquilo, heterociclilo, arilo, y heteroarilo están opcionalmente sustituidos con uno, dos o tres grupos RA, donde cada RA es independientemente RA2, alquilo C1-6, haloalquilo C1-4, arilo, arilalquilo C1-4 o alquilo -C1-4-RA2, donde el arilo del grupo arilalquilo C1-4 está opcionalmente sustituido con uno, dos o tres grupos RA2 donde, cada RA2 es independientemente halogeno, ciano, nitro, -ORA1, -SRA1, -N(RA1)2, -C(O)RA1, -S(O)RA1, -S(O)2RA1, -S(O)N(RA1)2, -S(O)2N(RA1)2, -C(O)ORA1, -C(O)N(RA1)2, -N(RA1)C(O)RA1, -N(RA1)C(O)ORA1, -N(RA1)C(O)N(RA1)2, -N(RA1)S(O)2RA1, -N(RA1)C(=NRA1)N(RA1)2, -P(O)(ORA1)2, o -OP(O)(ORA1)2, donde cada RA1 es independientemente hidrogeno, alquilo C1-4, o haloalquilo C1-4, o dos RA unidos a los átomos de carbono adyacentes, tomados juntos, forman -O-(G)y-O-, donde cada G es independientemente -CH2-, -C(H)(F)-, o -CF2-, y y es 1, 2, o 3; E es -(CH2)-, -C(H)(CH3)-, o -C(O)-; L es -[C(RL)2]p-L1-[C(RL)2]g-, donde p es 1, 2, o 3; q es un entero seleccionado de 0 a (3-p); L1 es un enlace, -O- o -NH- y cada RL es independientemente hidrogeno, metilo, o halometilo; R1 es -N(R10)(R11) o un resto de formula (2), donde R10 es hidrogeno o alquilo C1-4; R11 es -R13,-cicloalquilo C3-6-N(R12)2, -cicloalquilo C3-6-R13, alquilo C1-6-N(R12)2, o alquilo C1-6-R13, donde cada R12 es independientemente hidrogeno o alquilo C1-4; y R13 es (a) un anillo heterociclilo monocíclico de 4 a 10 miembros, bicíclico fusionado de 4 a 10 miembros, bicíclico puenteado de 5 a 10 miembros, o espirobicíclico de 5 a 10 miembros, donde el anillo heterociclilo comprende uno, dos o tres átomos de nitrogeno anular, y opcionalmente comprende un oxígeno anular o átomo de azufre, o (b) un heteroarilo monocíclico de 5 o 6 miembros o un heteroarilo bicíclico fusionado de 8 a 10 miembros, donde el carbono a los cuales éstos están unidos, forman un anillo fenilo; m es 0, 1, 2 o 3; n es 1, 2, o 3; y R5 es independientemente halogeno o alquilo C1-4, donde el grupo alquilo está opcionalmente sustituido con uno, dos, o tres grupos R51 donde cada R51 es independientemente hidroxi o halogeno; siempre que cuando X1 sea -N=, E es -C(O)-, L1 es un enlace o -NH-, A es isopropilo o t-butilo, R1 es un resto de formula (2), y el anillo B es pirrolidinilo, entonces R20 no es -C(O)ORB3 o -C(O)N(RB3)2; y R21, cuando está presente, es -C(O)ORB3 o -C(O)N(RB3)2; siempre que cuando L1 es un enlace, E es -CH2- o -CH(CH3)-, y Q es -NH-, entonces A no es isopropilo o ter-butilo; siempre que cuando L1 es un enlace, A es isopropilo o t-butil. E es -CH2- o -CH(CH3)-, y R1 es un resto de formula (2), entonces el anillo B no es pirazolilo, indazolilo, indolilo, o bencimidazolilo; siempre que cuando E es -CH2- o -CH(CH3)-, R1 es un resto de formula (2), entonces el anillo B es un anillo heterociclilo monocíclico de 4 a 10 miembros, entonces R20 y R21, cuando están presentes, no son arilalquilo C1-4; y siempre que cuando L1 es un enlace, E es -C(O)-, R1 es -N(R10)(R11), R11 es R13, y R13 es 8-azabiciclo[3,2,1]octanillo, entonces R13A, cuando está presente, no es arilalquilo C1-4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15043409P | 2009-02-06 | 2009-02-06 | |
| PCT/US2010/023080 WO2010091104A1 (en) | 2009-02-06 | 2010-02-03 | Glucosylceramide synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075367A1 true AR075367A1 (es) | 2011-03-30 |
Family
ID=42148396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100326A AR075367A1 (es) | 2009-02-06 | 2010-02-05 | Inhibidores de glucosilceramida sintasa |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR075367A1 (es) |
| TW (1) | TW201040156A (es) |
| WO (1) | WO2010091104A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018104472A (ru) * | 2011-03-18 | 2019-02-22 | Джензим Корпорейшн | Ингибиторы глюкозилцерамид-синтазы |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| JO3713B1 (ar) | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| AU2020218185B2 (en) | 2019-02-04 | 2025-01-23 | Genzyme Corporation | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) |
| RS65662B1 (sr) | 2019-11-15 | 2024-07-31 | Yuhan Corp | Derivati koji imaju 2,3-dihidro-1h-inden ili 2,3-dihidrobenzofuranski deo ili njihovu farmaceutski prihvatljivu so i farmaceutske kompozicije koje ih sadrže |
| KR20210059633A (ko) * | 2019-11-15 | 2021-05-25 | 주식회사유한양행 | 신규의 1,2,3,4-테트라하이드로나프탈렌 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
| AU2021215396A1 (en) | 2020-02-03 | 2022-09-29 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| WO2021221953A1 (en) | 2020-04-28 | 2021-11-04 | The Regents Of The University Of Michigan | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same |
| US11857512B2 (en) | 2020-07-24 | 2024-01-02 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| EP4213843A4 (en) * | 2020-09-17 | 2024-09-11 | Merck Sharp & Dohme LLC | MODIFIED IMIDAZOPYRIDINES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS |
| EP4213832A4 (en) * | 2020-09-18 | 2024-10-16 | Merck Sharp & Dohme LLC | Modified benzofuran-carboxamides as glucosylceramide synthase inhibitors |
| WO2023172475A2 (en) * | 2022-03-11 | 2023-09-14 | Merck Sharp & Dohme Llc | Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors |
| US20250171467A1 (en) * | 2022-03-14 | 2025-05-29 | Merck Sharp & Dohme Llc | Fused pyrazole amide analogs as glucosylceramide synthase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| ES2277745B1 (es) * | 2005-06-14 | 2008-06-01 | Laboratorios Almirall S.A. | Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1. |
| EP2594564B1 (en) * | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
-
2010
- 2010-02-03 WO PCT/US2010/023080 patent/WO2010091104A1/en not_active Ceased
- 2010-02-05 AR ARP100100326A patent/AR075367A1/es unknown
- 2010-02-06 TW TW099103670A patent/TW201040156A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201040156A (en) | 2010-11-16 |
| WO2010091104A8 (en) | 2011-04-07 |
| WO2010091104A1 (en) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075367A1 (es) | Inhibidores de glucosilceramida sintasa | |
| AR075368A1 (es) | Inhibidores de glicosilceramida sintasa | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR095328A1 (es) | Agentes de modulación de s1p y/o atx | |
| AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR088246A1 (es) | Derivados de etinilo | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| IL278036B1 (en) | Hpk1 inhibitors, preparation method and application thereof | |
| AR084731A1 (es) | Derivados de imidazoquinolina sustituidos | |
| CU20150054A7 (es) | Compuestos 1-carbonitrilo-6-amino aromáticos bicíclicos sustituidos como moduladores selectivos del receptor de andrógenos novedosos | |
| AR088414A1 (es) | Derivados sustituidos de indol | |
| AR118641A1 (es) | Compuestos, composiciones y métodos | |
| AR088765A1 (es) | Derivados de etinilo | |
| AR123543A1 (es) | DERIVADOS DE 2-(3-PIRIDIN-2-IL-4-QUINOLIN-4-IL-PIRAZOL-1-IL)-ACETAMIDA COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO TRANSFORMANTE b-1 / ALK5 | |
| AR122677A1 (es) | Nuevos compuestos de dicianuro de heterociclil-carbonohidrazonoílo fusionado y su uso | |
| AR084474A1 (es) | Compuestos heterociclicos como inhibidores de dgat1 | |
| ATE452636T1 (de) | 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |